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Abstract
Avian influenza A (H5N1) viruses represent a growing threat for an influenza pandemic. The 
presence of widespread avian influenza virus infections further emphasizes the need for vaccine 
strategies for control of prepandemic H5N1 and other avian influenza subtypes. Influenza 
neuraminidase (NA) vaccines represent a potential strategy for improving vaccines against avian 
influenza H5N1 viruses. To evaluate a strategy for NA vaccination, we generated a recombinant 
influenza virus-like particle (VLP) vaccine comprised of the NA protein of A/Indonesia/05/2005 
(H5N1) virus. Ferrets vaccinated with influenza N1 NA VLPs elicited high-titer serum NA-
inhibition (NI) antibody titers and were protected from lethal challenge with A/Indonesia/05/2005 
virus. Moreover, N1-immune ferrets shed less infectious virus than similarly challenged control 
animals. In contrast, ferrets administered control N2 NA VLPs were not protected against H5N1 
virus challenge. These results provide support for continued development of NA-based vaccines 
against influenza H5N1 viruses.
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1. Introduction
Hemagglutinin (HA) and neuraminidase (NA) are key surface glycoproteins of influenza A 
viruses. Following influenza virus infection, antibodies to both glycoproteins are produced, 
but the HA functions as the major antigen that induces protective immunity against influenza 
(Wilson and Cox, 1990). HA-specific antibodies efficiently neutralize influenza viruses of 
the same HA subtype and thus are highly potent at inhibiting viral replication. NA is less 
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abundant on the viral surface, but its enzymatic activity is important for cleaving sialic acid 
from the viral envelope, facilitating virus release from the surface of the infected cell 
(Matrosovich et al., 2004; Palese et al., 1974). Although less studied than anti-HA antibody 
responses, antibody to NA can block release of progeny viruses from the host cell and 
reduce the severity of influenza infection (Kilbourne et al., 1968; Murphy et al., 1972; Seto 
and Rott, 1966). NA-specific antibodies have been shown to reduce influenza virus 
replication and diminish lung pathology (Johansson et al., 1989; Schulman et al., 1968). 
Epidemiologic evidence in humans suggest that anti-NA antibodies induced by natural 
infection limit virus spread and reduce the severity of clinical illness (Beutner et al., 1979; 
Couch et al., 1974; Marcelin et al., 2011; Memoli et al., 2016; Monto and Kendal, 1973; 
Murphy et al., 1972; Smith and Davies, 1976).
Traditional inactivated influenza vaccines are composed of both HA and NA viral envelope 
glycoproteins. The amount of NA is not standardized in current influenza vaccines, and 
antibody responses to NA are generally weaker than those to the HA (Kilbourne et al., 1987; 
Wohlbold and Krammer, 2014). However, NA-based vaccines are a promising approach to 
improve influenza vaccines and offer a target of cross-protective immune responses against 
antigenic variants (Sylte and Suarez, 2009; Wohlbold and Krammer, 2014). NA antibodies 
are subtype-specific, binding to homologous and heterologous NAs within the same subtype 
(Lu et al., 2014; Sandbulte et al., 2007). A number of NA vaccines have been developed, 
including recombinant NA (rNA) proteins generated by expression systems that result in 
functional NA and protection against viral challenge (Bosch et al., 2010; Johansson et al., 
1998; Martinet et al., 1997; Wohlbold et al., 2015). rNA vaccines are capable of inducing NI 
antibodies that have been reported to suppress viral replication and disease in experimental 
animals (Deroo et al., 1996; Kilbourne et al., 2004). Lei et al. recently showed that NA 
presented on the surface of Lactococcus lactis provided protection against highly pathogenic 
avian influenza (HPAI) H5N1 virus in mice (Lei et al., 2015).
Repeated human exposure to the HPAI H5N1 virus has been well documented since 1997 
(http://www.who.int/en). This subtype presents a serious public health concern due to 
limited immunity in the population along with the ability of H5N1 virus to cause severe 
respiratory illness (Gambotto et al., 2008; Yu et al., 2008). From 2003 through May 2017, 
the World Health Organization (WHO) has confirmed 859 human cases of H5N1 infection 
with 453 deaths (http://www.who.int/en) and if this virus were to gain the capacity to spread 
efficiently among humans, a major pandemic would occur. Adhering to WHO’s 
recommendations, inactivated H5N1 virus vaccines for humans have been developed and 
licensed (http://www.who.int/influenza/en/). Like other inactivated influenza vaccines, 
H5N1 vaccines are based upon the induction of antibodies to the HA that are neutralizing 
and are often used to assess vaccine immunogenicity (Subbarao and Luke, 2007). However, 
less attention has been placed on developing NA vaccines, particularly for H5N1 virus. A 
NA vaccine may reduce the large disease burden of H5N1 virus infection and its associated 
high mortality. In this report, we describe the development and preclinical evaluation in a 
ferret model of an experimental NA virus-like particle (VLP) vaccine. Influenza VLPs are 
non-infectious, self-assembling protein structures that represent a useful recombinant 
vaccine approach with advantages in safety and manufacturing (Bright et al., 2008; Galarza 
et al., 2005; Perrone et al., 2009; Tretyakova et al., 2013). Here, VLP vaccines were 
Smith et al. Page 2
Virology. Author manuscript; available in PMC 2018 January 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
constructed from the N1 NA of A/Indonesia/05/2005 (clade 2.1.3.2) H5N1 virus or control 
N2 NA of A/Brisbane/10/2007 H3N2 virus. The N1 vaccines included two VLP groups 
(referred to as H3/N1/M1 and N1/M1) were directly compared to control N2 VLPs (H3/N2/
M1). N1/M1 VLPs were designed to study the effect of N1 without HA interference, while 
hybrid H3/N1/M1 VLPs were designed to serve as a control for the effect of heterosubtypic 
H3 and conserved M1. VLPs expressing homologous H5 HA (H5/N1/M1) representing a 
monovalent pandemic vaccine were also generated and used as the positive control vaccine 
for optimal protection. The investigational non-infectious N1 NA VLPs exhibited functional 
NA properties and induced high titers of NA-inhibiting (NI) antibodies. This work 
demonstrates the efficacy of a novel recombinant influenza NA-based VLP vaccine in ferrets 
to protect against HPAI H5N1 viral challenge.
2. Materials and methods
2.1. Viruses and cloning of HA, NA, and M1 genes
Influenza H5 HA, N1 NA and matrix M1 sequences of A/Indonesia/05/2005 (H5N1) virus 
were obtained from the NCBI Genbank with accession numbers ABP51969, ABW06107 
and ABI36004, respectively. Influenza H3 HA and N2 NA sequences of A/Brisbane/10/2007 
(H3N2) were obtained from the Genbank with accession numbers ACI26318 and ACI26321. 
All virus genes were codon-optimized for high-level expression in Spodoptera frugiperda 
(Sf9) insect cells (ATCC, Manassas, VA) and synthesized biochemically by Geneart 
(Regensburg, Germany). To generate constructs to express VLPs, full-length HA, NA and 
M1 genes were cloned into baculovirus (rBV) pFastBac1 transfer vectors between BamHI–
HindIII sites downstream from a polyhedrin promoter and subcloned into double/triple 
tandem vectors including HA/NA/M1 genes as described elsewhere (Smith et al., 2013). 
rBV expressing H3, H5, N1, N2 and M1 genes were generated by using a Bac-to-Bac 
baculovirus expression system (Life Technologies, Carlsbad, CA). The titers of rBV stocks 
were determined using plaque assays on Sf9 cells, expressed as plaque forming units 
(PFU)/ml. For expression of VLPs, Sf9 cells were maintained as suspension cultures in 
HyQ-SFX insect serum free medium (HyClone, Logan, UT) at 27 ± 2 °C. Recombinant 
baculovirus stocks were prepared as described (Liu et al., 2015). Briefly, Sf9 cells were 
infected at a low multiplicity of infection (MOI) of ≤ 0.01 pfu per cell and harvested at 68–
72 h post infection.
2.2. Production and purification of VLPs
The following four VLP vaccines were generated: H5/N1/M1, H3/N1/M1, H3/N2/M1, and 
N1/M1. Sf9 cells at 2 × 106 cells/ml were co-infected at an MOI of 0.5 pfu per cell with 
rBVs expressing H3, H5, N1, N2 and M1 genes. For the H5 HA gene, the site encoding 
RRKK amino acid residues was deleted from the natural polybasic furin cleavage site. After 
68–72 h, VLPs were harvested from the medium of baculovirus-infected Sf9 cells, incubated 
with continuous agitation at 27 ± 2 °C and harvested by centrifugation at 4000 × g for 15 
min. Cell culture supernatants containing VLPs were filtered with 0.45 μm membrane and 
purified with 25% sucrose gradient centrifugation. The purified VLPs were 0.2 μm sterile-
filtered, characterized and stored at 4 °C until vaccinations.
Smith et al. Page 3
Virology. Author manuscript; available in PMC 2018 January 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.3. Characterization of VLP vaccine
VLPs were analyzed by SDS-PAGE using 4–12% gradient polyacrylamide gel from Life 
Technologies (Carlsbad, CA), followed by staining with GelCode Blue commassie reagent 
(Pierce, Rockford, IL). Total protein concentrations of VLPs were determined by BCA 
bicinchoninic acid protein assay (Pierce Biochemicals, Rockford, IL). Particle size was 
determined by dynamic light scattering (DLS) with a Zetasizer Nano ZS (Malvern 
Instruments, PA). Western blot was performed using the primary antibodies of in house 
produced sheep anti-H5, rabbit anti-N1 and mouse anti-influenza A M1 (AbD Serotec, 
Kidlington, UK), and alkaline phosphatase labelled secondary antibodies rabbit anti-sheep, 
goat anti-rabbit and goat anti-mouse (KPL, Gaithersburg, MD).
The HA content in purified VLPs was measured using the single radial immunodiffusion 
(SRID) assay based on the protocol and reference standards from US Food and Drug 
Administration Center for Biologics Evaluation and Research (CBER). The SRID assay was 
performed as outlined in the original protocol (Schild et al., 1975). Sheep antisera raised in 
house against HA from A/Indonesia/05/2005 (H5N1) or A/Brisbane/10/07 (H3N2) and 
standard antigen of purified H5/N1/M1 or H3/N2/M1 VLPs were used in the H5N1 or H3N2 
SRID assay.
Stained VLPs were observed using transmission electron microscopy (TEM). Purified VLPs 
were applied to glow-discharged copper grids (400-mesh) that previously had been coated 
with carbon parlodion (Poly-Sciences, Warrington, PA). The grids were rinsed with buffer 
containing 10 mM Tris-HCl buffer (pH 7.4), negatively stained with 1% phosphotungstic 
acid, and dried by aspiration. VLPs were examined directly by TEM using a Hitachi H-7600 
(Hitachi High Technologies America, Schaumburg, IL) operating at 80 kV and incorporating 
a charge-coupled device (CCD) detector at 1k × 1k resolution (Advanced Microscopy 
Techniques Corp., Danvers, MA).
The NA-Fluor™ Influenza Neuraminidase Assay Kit (Life Technologies) was used for 
monitoring NA enzyme activity of VLPs according to manufacturer’s instructions. To 
generate a standard curve, 4-methylumbelliferone sodium salt (4-MU(SS), Sigma-Aldrich, 
St. Louis, MO) was used according to the NA-Fluor kit instructions. This kit is based on a 
96-well microplate format and includes the fluorescent methyl umbelliferone N-acetyl 
neuraminic acid (MUNANA) neuraminidase substrate.
2.4. Vaccinations and challenge
All experiments using H5N1 viruses, including work with animals, were performed in 
biosecurity level-3 enhanced (BSL-3E and ABSL-3E) facilities. Ferret experiments were 
performed under the guidance of the Centers for Disease Control and Prevention’s 
Institutional Animal Care and Use Committee and were conducted in an Association for 
Assessment and Accreditation of Laboratory Animal Care International-accredited animal 
facility. Adult male Fitch ferrets, 5–6 months of age (Triple F Farms, Sayre, PA), 
serologically negative by hemagglutination inhibition (HI) assay for currently circulating 
influenza viruses, were used in this study. Two vaccine experiments were conducted where 
groups of 4–5 ferrets received two intramuscular (i.m.) inoculations (4–5 weeks apart) of the 
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VLPs in a 0.5 ml volume. Ferrets were vaccinated with identical doses (2300 mU/ml) of 
VLPs based on NA activity. PBS treated ferrets served as unimmunized controls.
Prior to primary vaccination, vaccine boost, and viral challenge, all ferrets were bled for 
collection of serum to assess responses to vaccination. Ferrets were challenged intranasally 
(5 weeks following boost) with 106 PFU of A/Indonesia/05/2005 (H5N1) virus in a total 
volume of 1 ml (500 μl per nostril). Following challenge, ferrets were monitored daily for 
changes in body weight, temperature and clinical signs of illness. Any ferret that reached a 
clinical end point prior to the end of the 14 day experiment was humanely euthanized. Nasal 
wash samples were collected post-challenge (p.c.) on the days indicated, snap frozen on dry 
ice, and stored at −80 °C. Nasal wash samples were titrated in eggs to determine viral titers 
shed from infected ferrets, as previously described (Maines et al., 2005). The limit of virus 
detection was 101.5 EID50/ml. Weight loss and clinical signs of sneezing and nasal 
discharge, other respiratory distress, and level of activity were assessed daily. A scoring 
system was used to assess activity level where 0 = alert and playful; 1 = alert but playful 
only when stimulated; 2 = alert but not playful when stimulated; 3=neither alert nor playful 
when stimulated. Based on the daily scores for each animal in a group, a relative inactivity 
index was calculated (Zitzow et al., 2002). The statistical significance of differences in 
weight loss, temperature changes, and virus titers between vaccinated and PBS-control 
animals were determined by ANOVA.
2.5. Serological assays
All sera were initially diluted 1:10 in receptor-destroying enzyme from Vibrio cholerae 
(Denka Seiken, Tokyo, Japan). The HI assay was performed using 0.5% turkey or 1% horse 
red blood cells (RBCs) with 4 hemagglutination units (HAU) of homologous viruses using 
standard methods (Rowe et al., 1999). Titers of HI antibody are expressed as the reciprocal 
of the highest dilution of serum titer in which complete inhibition occurred. The HI titers are 
presented as the geometric mean titers (GMT) from vaccinated or control ferrets.
Antibodies with neuraminidase inhibition activity were detected using an Enzyme-Linked 
Lectin assay (ELLA) as previously described (Couzens et al., 2014). Briefly, two-fold 
serially diluted ferret sera were incubated with live H5N1 virus bearing target NA in 96 well 
plates coated with fetuin for 16–18 h. Next, horse radish peroxidase-labelled peanut 
agglutinin (lectin) was added to the reaction followed by TMB substrate to reveal enzymatic 
cleavage of fetuin by viral NA. The percent inhibition of NA enzymatic activity was 
calculated by comparison with values from virus control wells (virus but no serum). NA 
inhibition (NI) titer is expressed as the reciprocal of the highest dilution that exhibited at 
least 50% inhibition of NA activity.
3. Results
3.1. Expression and characterization of NA VLP Vaccines
For expression of VLPs, the baculovirus expression system in Sf9 cells was used. NA 
proteins from A/Indonesia/05/2005 (H5N1) and A/Brisbane/10/2007 (H3N2) viruses were 
used to generate NA VLP vaccines containing M1, which has been previously shown to be a 
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major structural component of influenza VLP complexes (Pushko et al., 2011, 2005). 
Experimental NA/M1 VLPs without HA were included along with a homologous H5 HA 
VLP (H5/N1/M1) that was used as the positive control vaccine for optimal protection (Fig. 
1A). The presence of specific H5 or H3 HA, N1 or N2 NA and M1 proteins in VLPs were 
confirmed by SDS-PAGE and Western blot with antibodies specific for the proteins. The 
protein composition of VLP preparations were analyzed by using equal protein quantities for 
Western blot analysis. The expressed H5 and H3 HA of the VLPs represented uncleaved 
HA0 polypeptides of approximately 65 and 75 kilodaltons (kDa), respectively (Fig. 1B). 
VLP preparations were prepared by sucrose centrifugation methods and expected to contain 
the residual infectious baculovirus that potentially can also include HA and NA antigens on 
the surface of recombinant baculoviruses. Baculovirus proteins were detected in the VLP 
preparations shown as baculovirus (BV) proteins gp64, p37 and p6.9 (Fig. 1B). Functionally, 
the NA VLPs displayed NA enzymatic activity after incubation with the MUNANA 
neuraminidase substrate. Comparable activity levels were observed between N1 NA VLPs 
and the control N2 NA VLP vaccine (Fig. 1C). Negative-staining transmission electron 
microscopy (TEM) identified the NA VLPs as largely spherical, typical influenza-like 
enveloped particles with characteristic spikes of NA protruding from the VLP envelope, 
which ranged from less than 100 nm to approximately 150 nm in diameter. TEM image of 
the four vaccines used in this study; H5/N1/M1, N1 VLPs (H3/N1/M1 & N1/M1), and 
control H3/N2/M1 VLPs are shown in Fig. 2.
3.2. Protective efficacy of N1 NA VLP vaccine to H5N1 virus challenge
We determined the level of protection in ferrets against H5N1 virus challenge induced by N1 
NA VLP vaccines. Vaccine protection was measured by reduction in (i) fever, (ii) weight 
loss, (iii) viral shedding, and (iv) mortality following intranasal A/Indonesia/05/2005 virus 
challenge. Overall, ferrets that were vaccinated with N1 VLPs (H3/N1/M1 and N1/M1) 
exhibited less fever compared to N2 VLP vaccinated (H3/N2/M2) and mock (PBS) 
vaccinated control animals (Table 1; experiment 1). Control vaccinated ferrets displayed 
high fever (mean maximum fever of 2.0–2.2 °C over baseline) peaking on day 3 p.c. (Fig. 
3A). N1-immune ferrets also experienced high fever, but there was a slight delay (days 4–5 
p.c.) in peak temperatures that were less than 1.9 °C over baseline. Vaccination with both N1 
VLP vaccine formulations resulted in significantly (p < 0.01) less weight loss compared to 
H3/N2/M1 vaccinated and mock control groups (Fig. 3B and Table 1). Following H5N1 
virus challenge, all six PBS mock-vaccinated ferrets showed a progressive loss of body 
weight and had to be euthanized by 6–7 days p.c. due to neurologic signs (uncontrolled 
movement or hind limb paralysis). Control N2 NA VLP-vaccinated ferrets also experienced 
substantial weight loss ranging from 9.9% to 13.7% with 100% (4 of 4) mortality (Fig. 3B 
and Table 1). In contrast, N1 VLP vaccines protected against severe H5N1 disease; 
H3/N1/M1 and N1/M1 vaccinated animals did not exhibit neurological signs and displayed 
survival rates of 100% and 75%, respectively (Table 1). The surviving ferrets showed 
moderate morbidity that reached a mean maximum weight loss of 5.2% and 8.6% for 
H3/N1/M1 and N1/M1 vaccinated animals, respectively (Fig. 3B and Table 1). As 
anticipated, ferrets that received the VLP vaccine expressing homologous (Indonesia/05) H5 
HA (H5/N1/M1 VLP) were well protected against substantial weight loss ( < 1.5%) and high 
fever (mean maximum fever of < 1.0 °C over baseline).
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The extent of virus shedding from the respiratory tract was determined by titrating nasal 
wash samples collected from immune and control ferrets following H5N1 virus challenge. In 
comparison to unimmunized PBS control animals, N1-immune (H3/N1/M1 and N1/M1) 
ferrets had a statistically significant reduction in viral shedding on days 4 and 6 p.c. (p < 
0.001) (Fig. 3C). Conversely, the control N2 NA VLP-vaccinated ferrets had similar titers to 
the mock-vaccinated control animals on both days measured. The positive control 
H5/N1/M1 VLP provided a high degree of protection against virus shedding on day 4 p.c. (p 
< 0.001) which fell below detectable limits by day 6 p.c. (Fig. 3C). These data indicate that 
although N1 VLPs do not provide sterilizing immunity against H5N1 virus challenge, these 
vaccines offered a significant level of protection against viral shedding and severe morbidity.
Similar protection results against H5N1 virus were observed in a repeat vaccine experiment. 
Because the two control groups (mock and N2 NA VLP-vaccinated) yielded similar levels of 
protection in the first study, only one control group, the N2 VLP vaccine, was included in 
the second experiment. This allowed for a greater number of animals (4–5) for each 
experimental group. As expected, the homologous H5/N1/M1 VLP vaccine offered excellent 
protection against A/Indonesia/05/2005 (H5N1) virus challenge (Fig. 4A). All H5/N1/M1 
VLP vaccinated ferrets survived challenge and lost minimal body weight (Table 1; 
experiment 2). Moreover, H5/N1/M1 vaccinated animals shed less infectious virus as 
compared to the control animals on days 2, 4 and 6 p.c. (Fig. 4B). In contrast, all ferrets that 
received the control N2 NA VLP vaccine showed severe weight loss and succumbed to 
H5N1 virus infection by day 7 p.c. (Table 1). Similar to the first experiment, H3/N1/M1 
VLP vaccinated ferrets were protected from severe disease and exhibited significantly less 
weight loss (p < 0.01) by day 5 post challenge. Although these vaccinated ferrets exhibited 
mean weight loss up to 11.9% and virus shedding titers up to 5.3 log10 EID50/ml, the 
H3/N1/M1 VLP vaccine protected 4 of 5 ferrets from neurological signs and death. The 
N1/M1 vaccinated ferrets were partially protected against H5N1 challenge, as indicated by 
reduced virus shedding on days 2, 4 and 6 p.c. (Fig. 4B) and 50% survival (Table 1). These 
results further support the use of recombinant NA VLPs as vaccines against H5N1 viruses.
3.3. NA VLP vaccines are efficient at inducing NA reactive antibodies
The immunogenicity of the NA VLP influenza vaccines in ferrets was assessed by 
hemagglutination and neuraminidase inhibition assays. Ferret sera were collected four 
(experiment 1) or five weeks (experiment 2) after the first immunization and prior to H5N1 
virus challenge. As expected, ferrets that received NA VLP influenza vaccines without H5 
HA did not exhibit any HI antibodies to the challenge H5N1 virus at any time point. The 
administration of one dose of H5/N1/M1 VLP vaccine resulted in HI titers that ranged from 
80 to 160 for both experiments (Table 2). Following the second immunization of H5/N1/M1 
VLP vaccine, the serum antibody response was further boosted and all the ferrets achieved 
HI titers of ≥160 to the homologous H5N1 virus. H3/N1/M1 and H3/N2/M1 vaccinated 
ferrets generated prechallenge HI antibody titers to H3N2 (A/Brisbane/10/2007) virus that 
ranged from 320 to 640 (not shown).
We next determined if NA-inhibiting (NI) antibody levels correlated with reduced viral 
shedding and disease severity among H5N1 challenged ferrets. We used the enzyme-linked 
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lectin assay (ELLA) to titer functional NI antibodies in ferrets immunized with VLPs. Prior 
to viral challenge, ferret sera were collected and examined by ELLA. As shown in Table 2, 
the ferret pre-vaccine serum did not show any significant NI titers to N1 of H5N1 (A/
Indonesia/05/2005) virus. Preimmune sera from experiment 2 showed higher background 
titers compared to the same sera in experiment 1, but these values were considerably lower 
than pre-challenge titers. All three N1 VLP immunized groups expressed high NI antibody 
titers against N1 compared to NI titers elicited by N2 VLP vaccination (Table 2). In both 
experiments, pre-challenge NI titers were highest in ferrets that had been immunized with a 
H5/N1/M1 VLP vaccine (GMT titers of 10240 and 4305) followed by the N1/M1 VLP 
(without HA) vaccinated group that elicited high-titer NI antibodies; GMT titers of 3620 and 
2153 were measured for experiments 1 and 2, respectively. NI GMTs following H3/N1/M1 
VLP vaccination also inhibited N1 (A/Indonesia/05/2005) NA activity efficiently that ranged 
from 320 to 1280 for the nine ferrets in both experiments. The ferrets administered control 
N2 NA VLPs, which were not protected against H5N1 virus challenge, had the lowest NI 
antibody titers in both experiments. Collectively, our results demonstrate that recombinant 
VLP vaccines comprised of NA protein of H5N1 virus generated substantially higher N1-
inhibiting antibodies among surviving ferrets, compared to NI titers of N2 NA-vaccinated 
ferrets that needed to be euthanized due to neurologic signs.
4. Discussion
The influenza virus HA is the target of antibodies for neutralization of infectivity. As a 
consequence, currently licensed inactivated influenza vaccines are standardized only by HA 
content. Although influenza vaccines predominantly induce protective anti-HA antibody 
titers, antibody responses to NA protein are formed following immunization or infection and 
can contribute to protection (Beutner et al., 1979; Couch et al., 1974; Marcelin et al., 2011; 
Monto and Kendal, 1973; Murphy et al., 1972; Smith and Davies, 1976). However, NA 
antibodies do not neutralize virus infectivity and anti-NA antibody levels induced by 
vaccination are variable, owing to the lack of standardization of NA protein content. More 
work is needed to clearly define the role of NA in protection against influenza and studies 
evaluating novel NA vaccine candidates will facilitate a greater understanding of the 
immune correlates of NA vaccine-induced protection. Here, we used the ferret model to 
demonstrate that N1 NA VLP vaccination could provide effective protection against an 
H5N1 (A/Indonesia/05/2005) clade 2.1.3.2 virus isolated from a fatal case in 2005. A/
Indonesia/05/2005 virus is among a group of highly virulent viruses able to spread to the 
brain of infected ferrets (Maines et al., 2006, 2005), and therefore provides a stringent 
challenge model for preclinical evaluation of influenza vaccines. The comparability of 
ELLA antibody titers for the analysis of NA VLP vaccine immunogenicity and the potential 
contribution of NI antibodies to protection demonstrated that high NI serum antibodies 
correlated with protection of ferrets against lethal H5N1 virus challenge.
Influenza vaccination against H5N1 is considered the best approach to prevent disease and 
its complications, including death (Subbarao and Luke, 2007). VLP technology allows for 
the safe production of influenza vaccines containing one or more surface glycoproteins 
stabilized by the matrix (M1) assembly protein (Kang et al., 2009; Pushko et al., 2010; Quan 
et al., 2016). Our approach in this study was to generate VLP vaccines expressing NA, 
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without homologous HA, and compare the protection efficacy conferred by a conventional 
HA-based VLP vaccine expressing homologous A/Indonesia/05/2005 HA protein. As 
demonstrated previously, VLPs containing H5 HA protect ferrets against lethal H5N1 
challenge as confirmed by reduced virus replication in the respiratory tract and protection 
against death (Pushko et al., 2011). In the current study, vaccination with N1 NA VLPs 
(H3/N1/M1 and N1/M1) did not reduce viral replication to the level observed among H5 HA 
(H5/N1/M1) vaccinated ferrets; however N1 NA VLP vaccination resulted in a 10- to 195-
fold reduction in viral load compared to control ferrets. Importantly, such a reduction was 
sufficient to protect against neurological signs and death in this model. Compared to the 
N1/M1 vaccine group, the N1 NA VLPs containing H3 HA (H3/N1/M1) provided slightly 
better protection following H5N1 virus challenge. The marginal improvement in body 
weight change and survival of H3/N1/M1 vaccinated ferrets may be due to certain limited 
pan-influenza A and/or stem based antibody or cellular responses elicited by H3. 
Conversely, the VLP vaccine containing control N2 NA (from seasonal H3N2 virus), which 
shares amino acid identity of only 42% to the N1 NA protein of A/Indonesia/05/2005 virus, 
and also the M1 contained in each VLP vaccine, failed to protect against neurological signs 
and death. The N2 NA was selected as the control VLP because NA genes exhibiting little 
sequence homology (40–46%) would not be expected to induce protective immunity 
(Colman and Ward, 1985; Wohlbold and Krammer, 2014; Wohlbold et al., 2015). The low 
cross-reactive NI antibody responses among N2 NA VLP vaccinated ferrets correlated with 
the lack of protection in this control group. Therefore, protection induced by the H3/N1/M1 
vaccine but not H3/N2/M1 VLPs makes it unlikely to be due to cross-reactive responses to 
viral antigens on the H3 HA, as the seasonal influenza A/Brisbane/10/2007 (H3) HA are 
present in both vaccines. Moreover, the N1/M1 VLP vaccine, without HA also provided 
protection against virus shedding and death.
NA activity is essential for efficient influenza virus replication and antibodies to 
neuraminidase inhibit viral spread (Matrosovich et al., 2004). The presence of NI titers in 
humans may offer partial protection during influenza epidemics and pandemics by reducing 
the clinical and epidemiological impact of influenza (Beutner et al., 1979; Brett and 
Johansson, 2005; Johansson, 1999; Kilbourne et al., 2002; Monto and Kendal, 1973; 
Murphy et al., 1972). In the current study, the presence of NI titers in vaccinated ferrets 
suggest that antibodies are binding to the globular NA head domains due to their ability to 
inhibit NA activity. Thus, the protection afforded by the N1 NA VLP vaccines is thought to 
be due to NI antibodies which likely function by reducing the efficiency of release of 
progeny virus from the surface of the infected cell (Johansson et al., 1998; Rott et al., 1974; 
Sylte et al., 2007; Webster et al., 1988). A protective NI titer is not clearly defined in animal 
vaccine studies and humans, however studies suggest that high levels of NI titers against 
influenza viruses are needed to provide protection in mice (Chen et al., 2000) and humans 
(Beutner et al., 1979; Kilbourne et al., 1995). In our hands, high NI titers were measured in 
protected ferrets against the homologous NA by the ELLA assay.
The relative conservation and slower antigenic evolution of NA, at least compared to HA1, 
suggest the use of NA as an influenza vaccine antigen (Frobert et al., 2010; Martinez et al., 
1983; Sandbulte et al., 2007; Westgeest et al., 2012). Influenza VLPs continue to provide 
attractive candidates for influenza vaccines (Bright et al., 2008; Galarza et al., 2005; Perrone 
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et al., 2009; Tretyakova et al., 2013). The protection demonstrated by using the stringent 
challenge model described here highlights the potential benefits of N1 NA candidate 
vaccines in a VLP platform against emerging avian influenza viruses. Because H5N1, and 
more recently H7N9 viruses, continue to cause outbreaks in poultry populations while 
posing a threat to humans, a better understanding of the potential of NA as a protective 
immunogen against these viruses may be an important step toward improving influenza 
vaccines.
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Fig. 1. Cloning and characterization of NA recombinant influenza virus-like particle (VLP)
VLPs were constructed in a baculovirus genetic background with the sequences of the genes 
for HA and NA sequences of A/Indonesia/05/2005 (H5N1) or A/Brisbane/10/2007 (H3N2) 
virus and produced in recombinant baculovirus infected Spodoptera frugiperda (Sf9) cells. 
(A) Influenza HA, NA and M1 genes were cloned into pFastBac1 baculovirus transfer vector 
in a tandem manner with each gene under a polyhedron promoter. The H5, N1, and M1 
genes were from A/Indonesia/05/2005 (H5N1); and H3 and N2 genes were from A/
Brisbane/10/2007 (H3N2). (B) Purified VLPs were analyzed using SDS-PAGE (left panel) 
and a Western blot against a mixture of sheep anti-H5, rabbit anti-N1 and mouse anti-
influenza A M1 serum (right panel). The identity of protein bands are labelled for influenza 
protein including H3 and H5 HA, N1 NA and M1, and baculovirus proteins gp64, p37 and 
p6.9. VLP samples were loaded at the same total protein levels. The sample in lane 1 
represents only 2 proteins (N1 and M1) compared to samples in lanes 2, 3, 4, which express 
3 proteins (HA, M1, N1). (C) Total protein concentration (BCA), SRID values for H5 and 
H3 HA; N1 and N2 NA activity by MUNANA assay. ND, not done.
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Fig. 2. Selected transmission electron microscope (TEM) micrographs of NA VLPs
VLPs containing NA were negatively stained with 1% phosphotungstic acid, and examined 
directly by TEM using a Hitachi H-7600. Bar, 100 nm.
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Fig. 3. Protective efficacy of NA VLP vaccines to A/Indonesia/05/2005 (H5N1) virus challenge in 
ferrets
Ferrets (4/vaccine group) received two intramuscular inoculations of VLP vaccines in a 0.5 
ml volume. Six ferrets received PBS in place of vaccine. Vaccine groups are as follows: 
H5/N1/M1 (▼), H3/N1/M1 (■), H3/N2/M1 (●), N1/M1 (▲), and mock (PBS) (◆). Ferrets 
were challenged intranasally (5 weeks following boost) with 106 PFU of A/Indonesia/
05/2005 (H5N1) virus and observed daily for body temperatures (A), and weight loss for 14 
days (B). Virus shedding was measured on 4 and 6 days post-challenge and is expressed as 
the log10 EID50/ml + SD (C). The weight loss among groups was analyzed by one-way 
ANOVA based on calculated Area Under the Curve (AUC) by day 6 post-challenge. Nasal 
wash titers among vaccine groups were analyzed by two-way ANOVA with GraphPad Prism 
software. ***p < 0.001, *p < 0.01, compared to PBS group.
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Fig. 4. Weight loss and viral shedding in NA-immune and control ferrets following H5N1 virus 
challenge
Ferrets (4–5/vaccine group) received two intramuscular inoculations of VLP vaccines in a 
0.5 ml volume and were challenged with 106 pfu of A/Indonesia/05/2005 (H5N1) virus five 
weeks after final vaccine boost. (A) Mean weight loss of ferrets following H5N1 virus 
challenge are shown at various days post challenge (p.c.). (B) Nasal washes were collected 
on indicated days p.c. and titrated for virus and are expressed as the log10 EID50/ml + SD. 
Weight loss by day 5 post challenge was analyzed by one-way ANOVA based on calculated 
AUC. Differences in viral titers of nasal washes between groups were analyzed by two-way 
ANOVA with GraphPad Prism software. ***p < 0.001, **p < 0.01, *p < 0.05 compared to 
control group.
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Table 1
Clinical signs observed in NA-immune ferrets challenged with H5N1 virus.
VLP vaccine groupa Clinical signs of H5N1 challenged ferrets
Max temp (°C)b % Weight Lossc Lethargyd Lethalitye
Experiment 1
H5/N1/M1 0.9 1.4 1.04 0/4
H3/N1/M1 1.7 5.2 1.07 0/4
H3/N2/M1 2.2 10.9 1.43 4/4
N1/M1 1.8 8.6 1.45 1/4
PBS 2.0 13.3 1.47 6/6
Experiment 2
H5/N1/M1 1.1 2.1 1.00 0/4
H3/N1/M1 1.5 11.9 1.22 1/5
H3/N2/M1 1.6 19.3 1.93 5/5
N1/M1 1.5 20.0 1.42 2/4
a
Ferrets were intramuscularly vaccinated twice (4–5 weeks apart) with NA VLP vaccines.
b
Mean maximum temperature increase over baseline.
c
Percentage mean maximum weight loss after challenge.
d
Relative inactivity index of ferrets during the first 10 days post-challenge.
eNumber of animals euthanized before the end of the 14 day experimental period
Virology. Author manuscript; available in PMC 2018 January 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Smith et al. Page 19
Table 2
Serum hemagglutination inhibition (HI) and enzyme-linked lectin assay (ELLA) antibody titers following NA 
VLP vaccination in ferretsa.
Vaccine group HI titerb ELLA titerb
Pre-boost Pre-challenge Pre-vaccine Pre-challenge
Experiment 1
H5/N1/M1 113 (80–160) 226 (160–320) 5 (5) 10240 (10240)
H3/N1/M1 < 10 < 10 5 (5) 905 (640–1280)
H3/N2/M1 < 10 < 10 5 (5) 47.6 (20–80)
N1/M1 < 10 < 10 5 (5) 3620 (2560–10240)
PBS < 10 < 10 5 (5) 5 (5)
Experiment 2
H5/N1/M1 135 (80–160) 320 (320) 14.1 (5–20) 4305 (2560–5120)
H3/N1/M1 < 10 < 10 11.9 (5–20) 403.2 (320–640)
H3/N2/M1 < 10 < 10 17.4 (10–20) 30.3 (20–40)
N1/M1 < 10 < 10 10 (5–20) 2153 (1280–2560)
a
Ferrets were intramuscularly vaccinated twice (4–5 weeks apart).
bSamples were tested for HI and ELLA antibody activity against A/Indonesia/05/2005 virus. Geometric mean titers (range in parentheses) are 
shown as the dilution of serum that inhibits agglutination of horse or turkey RBC’s or that exhibits ≥ 50% inhibition of NA enzymatic activity.
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